Zai Lab Limited (NASDAQ: ZLAB ) has proved its ability to adopt and commercialize new drugs in China, leveraging therapies already tested or approved elsewhere to minimize trial-related risk. This strategy has enabled the company to developI am an independent investor and analyst with a background in Biomedical Engineering. Currently pursuing a PhD in the field, I leverage my research skills and biotech expertise to critically assess publicly traded companies, focusing on their fundamentals. While my expert ...